Danaher Anticipates Performance to Reach High End of Prior Guidance

Deep News01-12

Danaher expects both its fourth-quarter revenue growth and full-year earnings to be near the high end of its previous performance forecast, boosted by strong performance in its bioprocessing business. The company stated it anticipates that adjusted core revenue growth for the fourth quarter will be near the upper limit of its prior guidance, which called for low single-digit percentage growth. The company also indicated it expects adjusted earnings per share for the entire 2025 fiscal year to be near the upper end of its previously projected range of $7.70 to $7.80. Chief Executive Officer Rainer Blair remarked, "We are particularly pleased with the continued strong performance of the bioprocessing business in the fourth quarter and the better-than-expected revenue from the life sciences and diagnostics businesses."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment